2,109 results on '"Mascola, John"'
Search Results
152. Prefusion-Stabilized Lassa Virus Trimer Identifies Neutralizing Nanobodies and Reveals an Apex-Situated Site of Vulnerability
153. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
154. Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants
155. Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2
156. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
157. Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice
158. Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses
159. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention
160. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron
161. Progress in the rational design of an AIDS vaccine
162. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
163. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial
164. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
165. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
166. Immunologic and Virologic Events in Early HIV Infection Predict Subsequent Rate of Progression
167. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
168. Protection of calves by a prefusion-stabilized bovine RSV F vaccine
169. Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120
170. Power to Detect the Effects of HIV Vaccination in Repeated Low-Dose Challenge Experiments
171. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
172. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
173. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
174. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys
175. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
176. Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition
177. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
178. Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
179. Gene Transfer in Humans Using a Conditionally Replicating Lentiviral Vector
180. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
181. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
182. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
183. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
184. Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine
185. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
186. Structure and immune recognition of trimeric pre-fusion HIV-1 Env
187. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
188. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1
189. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
190. Lessons from Failure: Preparing for Future HIV-1 Vaccine Efficacy Trials
191. HIV Immunology Goes Out On a Limb
192. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor
193. EBOLA VIRUS: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
194. Contributors
195. The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies
196. Preparation of Clinical-Grade Recombinant Canarypox-Human Immunodeficiency Virus Vaccine-Loaded Human Dendritic Cells
197. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
198. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
199. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial
200. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.